Newsletter

Stay up to date on all things coronary artery disease. Sign up and we’ll send you the latest news, resources, scientific breakthroughs, events, tips, and much more.

Make a comment and share this article on your profile.

Write a comment for your publication

Successfully Shared!

View on my Profile

Semaglutide Treatment On Coronary Progression

September 11, 2019

Overview

The Semaglutide Treatment On Coronary Progression (STOP) study aims to see the effect on Semaglutide (a diabetes medicine) on atherosclerosis (hardening of the arteries.) The study will look at the rate of change in total and non-calcified plaque volume in the arteries over 12 months.

 

Study Information

This is a randomized interventional study of 140 participants, is double blind placebo controlled and quadruple masked (participant, care provider, investigator, outcomes assessor.) Subjects will receive 2mg/1.5ml of Semaglutide in an injection or a placebo with the same pen injector.

 

Inclusion Criteria

  • Any gender
  • Ages 40+ at time of initial screening
  • Diagnosed with type 2 diabetes with a glycated hemoglobin level of 7.0% or more, drug naïve, or treated with oral agents and/or basal insulin. For patients on basal insulin at entry, the PI will consider dose reduction of basal insulin according to A1c and risk for hypoglycemia. Patients on SGLT-2 inhibitors may be screened but the agents must be discontinued at least 30 days prior to randomization.
  • Patients with at least one cardiovascular risk factor (hypertension, high cholesterol, family history of premature heart disease or past/current smoking) or prior ASCVD (prior stroke, TIA, claudication, coronary artery disease)
  • Willingness to participate in the study and ability to sign informed consent in the investigator’s opinion.

 

Exclusion Criteria

  • History of type 1 diabetes mellitus or a history of ketoacidosis.
  • Current use of GLP-1-receptor agonists or use of a GLP-1 receptor agonist within 3 mos. of screening.
  • Current Use of SGLT-2 inhibitors within 30 days of screening
  • Subjects on prandial insulin or using an insulin pump or pramlintide.
  • Any clinically significant malabsorption condition.
  • History of one or more severe hypoglycemic episodes within 6 months of Screening (V1) or a severe hypoglycemic episode occurring during the interval between the Screening visit (V1) and randomization.
  • Subjects experiencing a cardiovascular event (e.g., myocardial infarction or stroke) or undergoing coronary angioplasty or peripheral intervention procedure between the Screening visit (V1) and randomization.
  • Recent ASCVD Event (stroke, heart attack, ACS or revascularization) within 3 months (90 days) of the screening visit (VI).
  • Subjects undergoing any cardiovascular surgery (e.g., valvular surgery) within 3 months (90 days) of the Screening visit (V1).
  • Subjects with any planned coronary revascularization or peripheral intervention procedure or other cardiovascular surgery.
  • Subjects with New York Heart Association (NYHA) Class III or IV heart failure at the Screening visit (V1).
  • Renal insufficiency (calculated creatinine clearance of <50 ml per minute, MDRD equation).
  • AST or ALT >2 X the upper limit of normal (ULN) at the Screening visit (V1), or a total bilirubin >1.5 X the ULN unless the subject has a history of Gilbert’s.
  • Weight in excess of 325 pounds
  • Resting hypotension (systolic blood pressure of <90mmHg) or resting hypertension (systolic blood pressure of >170mmHg or diastolic blood pressure of >110 mmHg) or the treating physician is allowed to adjust background blood pressure medication(s) to lower blood pressure values in order for the subject to be reassessed for enrollment eligibility.
  • Subject has a history of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
  • Subject with a history of malignancy >5 years prior to signing informed consent should have no evidence of residual or recurrent disease.
  • Subject with any history of melanoma, leukemia, lymphoma, or renal cell carcinoma.
  • At randomization, the subject has developed a new medical condition, suffered a change in status of an established medical condition, developed a laboratory or ECG abnormality, or required a new treatment or medication during the pre-randomization period which meets any previously described trial exclusion criterion or which, in the opinion of the investigator, exposes the subject to risk by enrolling in the trial.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality at the Screening visit (V1) that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial.
  • Subjects with known allergy to iodinated contrast material
  • Subject is pregnant or breast-feeding, or is expecting to conceive during the trial, including 35 days following the last dose of blinded investigational product.
  • Females of childbearing potential must use adequate contraceptive methods.
  • Participation in other studies involving investigational drug (s) (Phases 1-4) within 30 days before the Screening visit (V1) and/or during trial participation.
  • Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC)
  • Personal history of non-familial medullary thyroid carcinoma.
  • Known or suspected hypersensitivity to trial products.

 

Location

Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center

Torrance, California, United States, 90502

Contact: Sajad Hamal, MS    310-974-9334 ext 7217 shamal@labiomed.org

 

Collaborators/Sponsors

Los Angeles Biomedical Research Institute

Clinical Trials

View All

Assessment of Biomarkers in Patients With Decompensated Heart Failure and Underlying Coronary Artery Disease

The Assessment of Biomarkers in Patients With Decompensated Heart Failure…

Cardiogoniometry for Detecting Coronary Artery Disease by CT Angiography

The Cardiogoniometry for Detecting Coronary Artery Disease by CT Angiography…

Is Our Microbiome a Predictor of Cardiac Risk?

The Is Our Microbiome a Predictor of Cardiac Risk? Study intends to see if…

Efficacy and Safety Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)

The Efficacy and Safety Study of 99mTc-ECDG in the Evaluation of Coronary…

Acute Vascular Response to Exercise in Women With Nonobstructive Coronary Artery Disease

The Acute Vascular Response to Exercise in Women With Nonobstructive Coronary Artery Disease study aims to research…

Coronary Atherosclerosis T1-Weighted Characterization (CATCH)

In the Coronary Atherosclerosis T1-Weighted Characterization (CATCH) study,…

Send this to a friend